Q1 Earnings Forecast for Lantheus Issued By Brookline Cap M

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Brookline Cap M issued their Q1 2026 earnings estimates for shares of Lantheus in a research report issued on Wednesday, February 11th. Brookline Cap M analyst K. Dolliver expects that the medical equipment provider will earn $1.03 per share for the quarter. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Brookline Cap M also issued estimates for Lantheus’ Q2 2026 earnings at $1.08 EPS and FY2026 earnings at $4.68 EPS.

LNTH has been the subject of a number of other research reports. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Truist Financial boosted their price objective on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Finally, Mizuho increased their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Stock Up 1.0%

Shares of NASDAQ:LNTH opened at $69.38 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. Lantheus has a 52-week low of $47.25 and a 52-week high of $111.29. The company has a market capitalization of $4.60 billion, a PE ratio of 29.15 and a beta of -0.08. The company has a fifty day moving average of $66.44 and a 200-day moving average of $59.37.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of LNTH. M&T Bank Corp purchased a new position in Lantheus in the fourth quarter valued at about $370,950,000. Assenagon Asset Management S.A. purchased a new position in shares of Lantheus during the 3rd quarter valued at $65,654,000. Norges Bank purchased a new stake in Lantheus in the 4th quarter worth about $76,197,000. Polaris Capital Management LLC bought a new stake in Lantheus in the 3rd quarter valued at about $32,687,000. Finally, Carmignac Gestion lifted its holdings in Lantheus by 39.0% during the fourth quarter. Carmignac Gestion now owns 1,122,000 shares of the medical equipment provider’s stock valued at $74,669,000 after purchasing an additional 314,591 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.